Delaying Substance Use Until Age 21 Linked to 83% Lower Polysubstance Risk

A national survey of 92,233 adults shows that early initiation before age 18 significantly increases the risk of multiple concurrent addictions.

For Doctors in a Hurry

Researchers investigated the prevalence of polysubstance use disorders and how the age of initial substance use affects these clinical outcomes.
This study analyzed data from 92,233 adult participants in the 2022-2023 US National Surveys on Drug Use and Health.
Adults initiating substance use at age 21 or older had 73 to 83 percent fewer substance use disorders (95% CI 0.12-0.31).
The authors concluded that early substance initiation before age 18 significantly increases the risk of developing multiple concurrent substance disorders.
Clinicians should prioritize prevention strategies for alcohol, cannabis, and nicotine use before age 21 to reduce long-term polysubstance morbidity.

The Clinical Burden of Concurrent Substance Use Disorders

Polysubstance use significantly complicates the clinical management of addiction, often leading to higher rates of non-fatal overdose and increased psychiatric comorbidity [1, 2]. Patients presenting with multiple substance dependencies frequently exhibit more severe affective symptoms and lower adherence to standard treatment protocols compared to those with a single diagnosis [3]. The risk for these complex trajectories is often rooted in early developmental windows, where individual impulsivity and environmental factors converge to increase vulnerability [4]. While the prevalence of certain substances fluctuates over time, the long-term burden of co-occurring addictions remains a primary driver of morbidity and mortality in adult populations [5]. To better understand this trajectory, a large-scale analysis of national survey data now clarifies the specific relationship between the timing of first substance use and the eventual development of multiple concurrent disorders, offering clinicians actionable insights for primary prevention.

Prevalence of Multiple Concurrent Addictions

To quantify the burden of co-occurring addictions, researchers analyzed data from 92,233 adult participants in the 2022-2023 US National Surveys on Drug Use and Health. The study focused on polysubstance use disorders, defined as the presence of two or more concurrent substance use disorders (SUDs). To determine how the age of first use influences the number of subsequent diagnoses, the authors applied multivariable logistic regression and Poisson regression (statistical techniques used to isolate specific risk factors and model the rate at which multiple diagnoses accumulate). Among adults diagnosed with at least one addiction, the age- and sex-adjusted past-year prevalence of having exactly two SUDs was 19.2-44.9% (95% CI, 11.1-62.3%).

The data further revealed that the risk of developing three or more concurrent disorders varied significantly depending on the primary substance involved. For instance, the age- and sex-adjusted past-year prevalence of three or more SUDs was 16.4% (95% CI, 14.3-18.6%) among adults with cannabis use disorder. This rate increased substantially for other substances. Among those with opioid use disorder, prescription stimulant use disorder, or tranquilizer/sedative use disorder, the prevalence of three or more SUDs ranged from 32.4-44.7% (95% CI, 29.1-51.3%).

The highest rates of complex polysubstance involvement were observed among users of illicit stimulants and hallucinogens. For adults with methamphetamine, cocaine, or hallucinogen use disorder, the prevalence of three or more concurrent SUDs reached 48.2-72.0% (95% CI, 39.4-81.7%). For the practicing physician, these findings indicate that a single-diagnosis clinical approach will likely fail to address the full scope of chemical dependency in patients using these specific substances. The high prevalence of multiple concurrent addictions across these cohorts underscores the absolute necessity of comprehensive screening for secondary and tertiary substance use during routine clinical assessments.

Impact of Initiation Age on Long-Term Risk

The researchers identified a strong correlation between the age of first substance use and the cumulative burden of addiction in adulthood. When compared to individuals who began using substances before the age of 18, those who delayed initiation until age 21 or older demonstrated a 73-83% lower total number of substance use disorders. To quantify this protective effect, the study utilized incidence density ratios (a metric comparing the rate of new diagnoses between different groups over time). For participants who waited until at least age 21 to initiate use, the incidence density ratios for the number of substance use disorders ranged from 0.17-0.27 (95% CI, 0.12-0.31). These figures suggest that delaying the onset of any substance use until the third decade of life significantly reduces the likelihood of developing the complex polysubstance profiles that often complicate clinical management.

The protective association of delayed initiation remained significant even when examining specific substances commonly used by young adults. For patients who began using alcohol between the ages of 21 and 29, the number of moderate-to-severe substance use disorders was 32% lower than for those who started before age 18, with an incidence density ratio of 0.68 (95% CI, 0.57-0.83). A similar trend was observed with cannabis. Initiating cannabis use at ages 21-29 was associated with a 21% lower number of moderate-to-severe substance use disorders compared to initiation before age 18, supported by an incidence density ratio of 0.79 (95% CI, 0.69-0.90). For the practicing clinician, these data emphasize that every year initiation is delayed during adolescence and early adulthood correlates with a measurable reduction in the risk of developing multiple severe addictions later in life.

The Protective Effect of Abstinence from Gateway Substances

The study further examined the long-term outcomes of individuals who completely avoided substances often considered precursors to more complex addiction profiles. For clinicians focused on primary prevention, the data regarding complete abstinence from alcohol, cannabis, and nicotine are particularly instructive. The researchers found that adults who never initiated the use of alcohol, cannabis, or nicotine had a 45-62% lower number of moderate-to-severe substance use disorders when compared to those who began using substances before the age of 18. This finding highlights the substantial protective benefit of avoiding these specific substances during the critical window of neurodevelopment in adolescence.

Quantifying this reduction in risk, the authors reported that for the group that never initiated alcohol, cannabis, or nicotine, the incidence density ratios for moderate-to-severe substance use disorders ranged from 0.38-0.55 (95% CI, 0.31-0.76). These statistics underscore that the absence of early exposure to these substances is strongly associated with a decreased likelihood of developing multiple clinically significant addictions in adulthood.

From a clinical perspective, these findings suggest that preventing the initiation of any substance use before age 21 serves as a vital primary intervention. By delaying or preventing the use of nicotine, alcohol, and cannabis, healthcare providers may significantly reduce the risk that a patient will later present with the complex multi-substance addiction profiles that are notoriously difficult to treat. The data support a clear clinical objective. Evidence-based strategies aimed at preventing substance consumption before age 21 are essential for mitigating the long-term burden of polysubstance use disorders in adult populations.

Study Info

Polysubstance use disorders among US adults.

Beth Han, Nora D Volkow, Christopher M Jones, Deborah Dowell, et al.

Journal Molecular psychiatry

Published April 29, 2026